FindTrial
Sign In

Effect of preemptive analgesia with furbiprofen axetil or nalbuphine following hydroxyapatite orbital implantation: a single-center, prospective, randomized controlled trial

Effect of preemptive analgesia with furbiprofen axetil or nalbuphine following hydroxyapatite orbital implantation: a single-center, prospective, randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026927
Enrollment
Unknown
Registered
2019-10-26
Start date
2019-10-25
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hydroxyapatite orbital implantation

Interventions

Group F:Preemptive administration of intravenous furbiprofen axetil
Group N:Preemptive administration of intravenous nalbuphine
Group C:Preemptive administration of intravenous furbiprofen axetil and nalbuphine

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-sun University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16-65 years old; 2. patients receiving hydroxyapatite orbital implantation under general anesthesia (only primary surgery).

Exclusion criteria

Exclusion criteria: 1. inability to communicate (including impairment of sensorium); 2. inability to provide informed consent; 3. with mental illness; 4. any other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
mean NRS score at 24 hours after the surgery;NRS score;—

Secondary

MeasureTime frame
demographics of the patients;surgery related characteristics;incidence of postoperative complication;postoperative medication;postoperative discomfort;—

Countries

China

Contacts

Public ContactYanling Zhu

Zhongshan Ophthalmic Center, Sun Yat-sun University

gzyan03@163.com+86 18898600243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026